bibliographic entry 12595372 [be/12595372]
https://w3id.org/oc/corpus/be/12595372

is a

• bibliographic reference

content

• Stintzig, SJA, Rossius, L. Analysis of KRAS/NRAS and BRAF mutations in FIRE-3: a randomized phase III study of FOLFIRI plus cetuximab or bevacizumab as first-line treatment for wild-type (WT) KRAS (exon 2) metastatic colorectal cancer (mCRC) patients, Paper presented at: European Cancer Congress, 2013

references

• https://w3id.org/oc/corpus/br/4723821